Allogene Therapeutics (ALLO) Enterprise Value (2018 - 2026)
Allogene Therapeutics recorded quarterly Enterprise Value of -$266.9 million in Q1 2026, down 6.66% quarter-over-quarter from -$250.2 million in Q4 2025, and up 3.21% year-over-year from -$258.6 million in Q1 2025.
Allogene Therapeutics' Enterprise Value history runs 9 years deep, the most recent figure standing at -$266.9 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 3.21% year-over-year to -$266.9 million; the TTM figure through Mar 2026 stood at -$266.9 million (up 3.21% YoY), while the FY2025 annual figure was -$250.2 million, up 14.45% from the prior year.
- Enterprise Value came in at -$266.9 million for Q1 2026 at Allogene Therapeutics, down from -$250.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$246.0 million in Q3 2025 to a low of -$552.2 million in Q3 2022.
- A 5-year average of -$385.1 million and a median of -$435.5 million in 2024 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value declined 16.84% in 2022 and soared 37.37% in 2024, its largest moves.
- Allogene Therapeutics' Enterprise Value stood at -$467.2 million in 2022, then rose by 3.96% to -$448.7 million in 2023, then surged by 34.82% to -$292.5 million in 2024, then advanced by 14.45% to -$250.2 million in 2025, then decreased by 6.66% to -$266.9 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$266.9 million, -$250.2 million, and -$246.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Allogene Therapeutics | 521.43 Mn | 521.43 Mn | - | -266.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -266.89 Mn |
| Dec 31, 2025 | -250.21 Mn |
| Sep 30, 2025 | -245.98 Mn |
| Jun 30, 2025 | -273.12 Mn |
| Mar 31, 2025 | -275.72 Mn |
| Dec 31, 2024 | -292.48 Mn |
| Sep 30, 2024 | -291.56 Mn |
| Jun 30, 2024 | -435.50 Mn |
| Mar 31, 2024 | -378.84 Mn |
| Dec 31, 2023 | -448.70 Mn |
| Sep 30, 2023 | -465.51 Mn |
| Jun 30, 2023 | -491.96 Mn |
| Mar 31, 2023 | -471.22 Mn |
| Dec 31, 2022 | -467.18 Mn |
| Sep 30, 2022 | -552.23 Mn |
| Jun 30, 2022 | -490.49 Mn |
| Mar 31, 2022 | -449.05 Mn |
| Dec 31, 2021 | -399.86 Mn |
| Sep 30, 2021 | -483.49 Mn |
| Jun 30, 2021 | -533.93 Mn |
| Mar 31, 2021 | -639.34 Mn |
| Dec 31, 2020 | -746.60 Mn |
| Sep 30, 2020 | -783.95 Mn |
| Jun 30, 2020 | -899.65 Mn |
| Mar 31, 2020 | -492.92 Mn |
| Dec 31, 2019 | -478.31 Mn |
| Sep 30, 2019 | -501.24 Mn |
| Jun 30, 2019 | -502.42 Mn |
| Mar 31, 2019 | -1.05 Bn |
| Dec 31, 2018 | -452.17 Mn |
| Sep 30, 2018 | -559.38 Mn |